dimethyl itaconate has been researched along with Colitis-Associated Cancer in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, GH; Fan, W; Feng, GK; Li, XL; Mei, Y; Wang, Q; Ye, JC; Zeng, MS | 1 |
1 other study(ies) available for dimethyl itaconate and Colitis-Associated Cancer
| Article | Year |
|---|---|
The anti-inflammatory drug dimethyl itaconate protects against colitis-associated colorectal cancer.
Topics: Animals; Anti-Inflammatory Agents; Colitis-Associated Neoplasms; Colitis, Ulcerative; Cytokines; Disease Models, Animal; Humans; Inflammation Mediators; Macrophages; Mice; Protective Agents; Succinates | 2020 |